Scarica l'app Stockscreener
42.53
2.38%
0.99
Dopo l'orario di chiusura:
42.53
Precedente Chiudi:
$41.54
Aprire:
$42.04
Volume 24 ore:
538.93K
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.59B
Reddito:
-
Utile/perdita netta:
$-103.69M
Rapporto P/E:
-22.89
EPS:
-1.8579
Flusso di cassa netto:
$-70.46M
1 W Prestazione:
+5.88%
1M Prestazione:
-3.89%
6M Prestazione:
+95.90%
1 anno Prestazione:
+159.33%
Intervallo 1D:
$40.73
$42.59
Intervallo di 1 settimana:
$40.30
$43.05
Portata 52W:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
42.53 | 2.53B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
ELVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Technical Signals Behind (ELVN) That Institutions Follow - Stock Traders Daily
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - The Chronicle-Journal
ELVN Technical Analysis & Stock Price Forecast - Intellectia AI
Biopharma Enliven joins TD Cowen, Jefferies investor chats online - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - Moomoo
ELVN News | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
Enliven Therapeutics CMO sells $198,971 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CMO sells $198,971 in stock - Investing.com
Enliven Therapeutics (ELVN) CMO trades 5,000 shares and exercises 5,000 options - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) proposed 15,000-share sale via Jefferies - Stock Titan
Polar Capital (ELVN) discloses 5.06M shares; 8.46% ownership reported - Stock Titan
Vestal Point / Ryan Wilder report 3.25M shares in Enliven Therapeutics (ELVN) - Stock Titan
Venrock group discloses 1.73M ELVN shares (2.8% of float) - Stock Titan
Fairmount files 13G/A: 1.86M shares (3.1%) in Enliven Therapeutics (ELVN) - Stock Titan
Commodore holds 4.8M shares in Enliven (NASDAQ: ELVN) after amendment - Stock Titan
Polar Capital (ELVN) discloses 5.07M shares, 8.47% stake in ENLIVEN - Stock Titan
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Enliven Therapeutics (ELVN) Slips -3.15%, Testing $40.08 Support 2026-05-14Hot Stocks - newser.com
ELVN stock climbs as Guggenheim launches coverage with $80 price target ahead of conference data unveil - MSN
Precision Trading with Enliven Therapeutics Inc. (ELVN) Risk Zones - Stock Traders Daily
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil - Stocktwits
Enliven to present updated ELVN-001 leukemia trial data at EHA By Investing.com - Investing.com South Africa
Enliven to present updated ELVN-001 leukemia trial data at EHA - Investing.com Australia
Enliven Therapeutics Insiders Sell US$644k Of Stock, Possibly Signalling Caution - Moomoo
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - PR Newswire
Guggenheim Initiates Coverage on Enliven Therapeutics With Buy, $80 Price Target - marketscreener.com
A Look At Enliven Therapeutics (ELVN) Valuation After Analyst Support And Phase 3 Trial Plans - Sahm
TradingKey - TradingKey
Guggenheim initiates Enliven Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Guggenheim Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $80 - Moomoo
Merck & Co. Inc. (MRK)Strategic Investment Implications from Clinical-Stage Oncology Pipeline DevelopmentsCompetitive Risk - newser.com
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026? - Insider Monkey
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - Quantisnow
Enliven: Drug candidate ‘has the potential to be the best-in-class’ - BizWest
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $59 - Moomoo
Enliven Therapeutics, Inc. (ELVN) - DirectorsTalk Interviews
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $45 - Moomoo
Enliven Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Q1 2026: Enliven Therapeutics (NASDAQ: ELVN) narrows loss, holds $452M cash - Stock Titan
Enliven Therapeutics Q1 net loss narrows as R&D spending reduces - TradingView
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) narrows loss and targets Phase 3 trial - Stock Titan
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - marketscreener.com
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):